Edition:
India

Alkem Laboratories Ltd (ALKE.NS)

ALKE.NS on National Stock Exchange of India

1,972.00INR
11 Nov 2019
Change (% chg)

Rs-62.25 (-3.06%)
Prev Close
Rs2,034.25
Open
Rs2,025.90
Day's High
Rs2,068.75
Day's Low
Rs1,940.80
Volume
161,949
Avg. Vol
43,483
52-wk High
Rs2,079.00
52-wk Low
Rs1,660.00

Latest Key Developments (Source: Significant Developments)

India's Alkem Labs St. Louis Plant Gets FDA Form 483 With 4 Observations
Wednesday, 11 Sep 2019 

Sept 11 (Reuters) - Alkem Laboratories Ltd ::INDIA'S ALKEM LABS SAYS US FDA HAS ISSUED AN ESTABLISHMENT INSPECTION REPORT FOR COMPANY'S MANUFACTURING FACILITY LOCATED AT ST. LOUIS.SAYS RECEIVED A FORM 483 ISSUED BY US FDA CONTAINING FOUR OBSERVATIONS.SAYS INSPECTION HAS NOW BEEN CLOSED BY US FDA.  Full Article

India's Alkem Labs Says Got U.S. FDA Form 483 With Two Observations For Daman Unit
Friday, 30 Aug 2019 

Aug 30 (Reuters) - Alkem Laboratories Ltd ::SAYS US FDA HAD CONDUCTED AN INSPECTION AT COMPANY'S MANUFACTURING FACILITY LOCATED AT DAMAN, INDIA.SAYS COMPANY HAS RECEIVED A FORM 483 WITH TWO (2) OBSERVATIONS.SAYS SHALL PUT TOGETHER A RESPONSE WITH ADEQUATE CORRECTIVE AND PREVENTIVE MEASURES TO ADDRESS US FDA OBSERVATIONS.  Full Article

India's Alkem Laboratories June-Qtr Consol Net Profit Rises
Monday, 12 Aug 2019 

Aug 12 (Reuters) - Alkem Laboratories Ltd ::JUNE QUARTER CONSOL NET PROFIT 1.85 BILLION RUPEES VERSUS 1.36 BILLION RUPEES YEAR AGO.JUNE QUARTER CONSOL REVENUE FROM OPERATIONS 18.50 BILLION RUPEES VERSUS 16.59 BILLION RUPEES YEAR AGO.  Full Article

India's Alkem Laboratories March-Qtr Consol Net Profit Rises
Thursday, 30 May 2019 

May 30 (Reuters) - Alkem Laboratories Ltd ::MARCH QUARTER CONSOL NET PROFIT 1.67 BILLION RUPEES VERSUS 670.8 MILLION RUPEES YEAR AGO.MARCH QUARTER CONSOL REVENUE FROM OPERATIONS 18.54 BILLION RUPEES VERSUS 14.92 BILLION RUPEES YEAR AGO.RECOMMENDED FINAL DIVIDEND OF 8 RUPEES PER SHARE.APPROVED RE-APPOINTMENT OF SAMPRADA SINGH AS CHAIRMAN EMERITUS.APPROVED RE-APPOINTMENT OF BASUDEO N. SINGH AS EXECUTIVE CHAIRMAN.  Full Article

Alkem Labs Says Product Not Being Made At This Time At St Louis Facilty as it Awaits USFDA approval
Friday, 22 Mar 2019 

March 22 (Reuters) - Alkem Laboratories Ltd ::ALKEM LABORATORIES -SUBMITTED RESPONSE TO THE 8 FORM 483 OBSERVATIONS RECEIVED DURING PRE-APPROVAL INSPECTION FOR PRODUCT AT FACILITY AT ST. LOUIS.ALKEM LABORATORIES - SAID PRODUCT IS NOT BEING MANUFACTURED AT THIS TIME AS IT IS AWAITING APPROVAL FROM US FDA..  Full Article

India's Alkem Laboratories Says U.S FDA Inspection At Manufacturing Facility At Daman
Friday, 18 Jan 2019 

Jan 18 (Reuters) - Alkem Laboratories Ltd ::SAYS US FDA INSPECTION AT ALKEM'S MANUFACTURING FACILITY LOCATED AT DAMAN, INDIA..SAYS AT THE END OF THE INSPECTION NO FORM 483 WAS ISSUED.  Full Article

Alkem Laboratories Gets Shareholders' Nod For Continuance Of Samprada Singh Designated As Chairman Emeritus
Monday, 7 Jan 2019 

Jan 7 (Reuters) - Alkem Laboratories Ltd ::GETS SHAREHOLDERS' NOD FOR CONTINUANCE OF SAMPRADA SINGH DESIGNATED AS CHAIRMAN EMERITUS.  Full Article

India's Alkem Laboratories Says Closure Of U.S FDA Inspection At St.Louis manufacturing Facility
Tuesday, 4 Dec 2018 

Dec 4 (Reuters) - Alkem Laboratories Ltd ::US FDA ISSUED ESTABLISHMENT INSPECTION REPORT FOR CO'S MANUFACTURING FACILITY LOCATED AT ST. LOUIS, USA.IN RESPONSE TO FORM 483 ISSUED BY US FDA WITH 1 OBSERVATION, CO SUBMITTED DETAILED CORRECTIVE AND PREVENTIVE ACTION PLAN.SAYS INSPECTION HAS NOW BEEN CLOSED BY THE US FDA.  Full Article

Alkem Labs Says Co Submitted Corrective Action Plan To Regulator For EIR For Daman Plant
Tuesday, 24 Jul 2018 

July 24 (Reuters) - Alkem Laboratories Ltd ::ALKEM LABORATORIES -US FDA HAS ISSUED AN ESTABLISHMENT INSPECTION REPORT (EIR) FOR COMPANY'S MANUFACTURING FACILITY LOCATED AT AMALIYA, DAMAN.SAYS INSPECTION HAS NOW BEEN CLOSED BY US FDA.SAYS INSPECTION OF UNIT WAS FROM 19TH MARCH TO 27TH MARCH.  Full Article

India's Alkem Labs March-Qtr Consol Profit More Than Halves
Wednesday, 30 May 2018 

May 30 (Reuters) - Alkem Laboratories Ltd ::MARCH QUARTER CONSOL PROFIT 670.8 MILLION RUPEES VERSUS PROFIT 1.37 BILLION RUPEES YEAR AGO.MARCH QUARTER CONSOL REVENUE FROM OPERATIONS 15.13 BLNRUPEES VERSUS 12.51 BILLION RUPEES YEAR AGO.RECOMMENDED DIVIDEND OF 7 RUPEES PER SHARE.  Full Article